Drugs / Rituximab and Hyaluronidase Human
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03719131 | Jun 2019 → Sep 2022 | cutaneous melanoma | Emory University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-06-22 | Genentech, Inc. | Regulatory FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers gene.com ↗
FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-06-22 | Genentech, Inc. | FDA Approves Rituxan Hycela (Rituximab and Hyaluronidase Human) for Subcutaneous Injection in Certain Blood Cancers gene.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rituximab and Hyaluronidase Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03719131 ↗ |
| Route | Intravenous | “Given IV or SC” NCT03719131 ↗ |
| Route | Subcutaneous | “Given IV or SC” NCT03719131 ↗ |